Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253342 · ClinicalTrials.gov registry record · Phase 1
Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects
A Phase 1 study, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02253342 is a Phase 1 study that has completed, run by Wockhardt. The registered enrollment target is 30 participants.
The verdict
NCT02253342, a Phase 1 study, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study to determine and compare plasma, epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of levonadifloxacin after administration of WCK 2349 in healthy adult subjects.
Interventions
- DRUG WCK-2349
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253342
The ClinicalTrials.gov registry entry for NCT02253342 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WCK-2349 is the first listed.
NCT02253342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02253342 about?
NCT02253342 is a clinical study titled "Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects". This study to determine and compare plasma, epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of levonadifloxacin after administration of WCK 2349 in healthy adult subjects.
What is the current status of trial NCT02253342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02253342?
The interventions under investigation include: WCK-2349 (DRUG).
Who is sponsoring clinical trial NCT02253342?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.